INT25666

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1986
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 11
Total Number 13
Disease Relevance 3.12
Pain Relevance 2.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (ADRB1) plasma membrane (ADRB1) nucleus (ADRB1)
cytoplasm (ADRB1) signal transducer activity (ADRB1)
Anatomy Link Frequency
myometrium 1
smooth muscle 1
body 1
ADRB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 12 100.00 Very High Very High Very High
depression 1 98.64 Very High Very High Very High
local anesthetic 10 96.00 Very High Very High Very High
Clonidine 7 92.96 High High
Potency 3 88.60 High High
Pain 1 87.64 High High
nerve block 1 83.96 Quite High
noradrenaline 4 82.52 Quite High
imagery 3 80.76 Quite High
transdermal 3 78.48 Quite High
Disease Link Frequency Relevance Heat
Overdose 1 99.40 Very High Very High Very High
Obesity 14 98.82 Very High Very High Very High
Cardiovascular Disorder Under Development 1 98.64 Very High Very High Very High
Osteoporosis 2 98.44 Very High Very High Very High
Parasitemia 27 92.04 High High
Pain 2 87.64 High High
Polycystic Ovary Syndrome 12 75.00 Quite High
Weight Loss 6 75.00 Quite High
Malaria 123 71.84 Quite High
Cv General 3 Under Development 2 70.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Finally, the relatively potent inhibition of beta2ARs by etidocaine, tetracaine, and bupivacaine suggests that their propensity for cardiovascular depression after accidental intravenous overdose could result from beta2AR or beta1AR blockade and inhibition of cAMP production.
Negative_regulation (blockade) of beta1AR associated with depression, overdose and cardiovascular disorder under development
1) Confidence 0.44 Published 1997 Journal Anesth. Analg. Section Abstract Doc Link 9249110 Disease Relevance 0.20 Pain Relevance 0.85
Whereas the existence of the third ADRB subtype had not been shown yet formally, we previously described that ADRB2 were predominant (65%) over ADRB1 in the human myometrium and that the number of ADRB was diminished at the end of pregnancy [20].
Negative_regulation (number) of ADRB in myometrium
2) Confidence 0.42 Published 2007 Journal BMC Pregnancy Childbirth Section Body Doc Link PMC1892055 Disease Relevance 0 Pain Relevance 0.21
The results indicated a significant 24.2% reduction of the beta-1 receptor and a 25.4% reduction in G protein stimulation.
Negative_regulation (reduction) of beta-1 receptor
3) Confidence 0.37 Published 1989 Journal J. Surg. Res. Section Abstract Doc Link 2536864 Disease Relevance 0.06 Pain Relevance 0.07
The beta-1 receptor responsiveness was also significantly (P less than 0.02) decreased but not the receptor sensitivity.
Negative_regulation (decreased) of beta-1 receptor
4) Confidence 0.37 Published 1989 Journal J. Surg. Res. Section Abstract Doc Link 2536864 Disease Relevance 0.08 Pain Relevance 0.08
Bevantolol hydrochloride, a beta adrenoceptor antagonist, can be categorized using conventional schemes as being cardioselective, devoid of intrinsic sympathomimetic activity and having weak membrane-stabilizing and local anesthetic properties.
Negative_regulation (antagonist) of adrenoceptor associated with antagonist and local anesthetic
5) Confidence 0.37 Published 1986 Journal Angiology Section Abstract Doc Link 2871786 Disease Relevance 0.06 Pain Relevance 0.14
CR metoprolol 50 or 100mg and conventional release atenolol 50mg, each given once daily, provided effective beta1-adrenoceptor blockade.
Negative_regulation (blockade) of beta1-adrenoceptor
6) Confidence 0.35 Published 1994 Journal Pharmacoeconomics Section Abstract Doc Link 10150160 Disease Relevance 0.32 Pain Relevance 0.36
These experiments indicate that AY-28,925 possesses, in decreasing orders of activity: nonselective beta-adrenoceptor properties; a selective alpha-1 adrenoceptor inhibitory effect; and a nonspecific direct relaxing action on vascular smooth muscle.
Negative_regulation (effect) of adrenoceptor in smooth muscle
7) Confidence 0.13 Published 1986 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2876089 Disease Relevance 0 Pain Relevance 0.15
Freezing merozoite pellets, increased ADRB activity somewhat (Figure 1D), but antibody complexes with putative cytosolic antigens did not explain the increase, since merozoite sonication abrogated most ADRB activity (Figure 1D).
Negative_regulation (abrogated) of ADRB
8) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2845614 Disease Relevance 0 Pain Relevance 0.04
Following multivariate analysis described in Materials and Methods, two alternative models were proposed: (i) using continuously decreasing ADRB index (RR?
Negative_regulation (decreasing) of ADRB
9) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2845614 Disease Relevance 0.35 Pain Relevance 0
After multivariate analysis, three alternative models were proposed using: (i) continuously decreasing ADRB index (RR?
Negative_regulation (decreasing) of ADRB
10) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2845614 Disease Relevance 0.15 Pain Relevance 0
Pre-operative joint destruction (grade 1), a high degree of radiological osteoporosis, a body mass index >25 and prosthesis mismatch were significantly related to failure of the RHR.
Negative_regulation (failure) of RHR in body associated with obesity and osteoporosis
11) Confidence 0.06 Published 2005 Journal Int Orthop Section Abstract Doc Link 15856230 Disease Relevance 0.47 Pain Relevance 0.09
OC treatment did not influence the basal lipolysis rate or beta2- or alpha2-adrenoceptor sensitivity, but lowered the beta1-adrenoceptor sensitivity 7-fold (P < 0.03) without a reduction in beta1-adrenoceptor density.
Negative_regulation (reduction) of beta1-adrenoceptor
12) Confidence 0.03 Published 1999 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10372729 Disease Relevance 0.70 Pain Relevance 0.17
OC treatment did not influence the basal lipolysis rate or beta2- or alpha2-adrenoceptor sensitivity, but lowered the beta1-adrenoceptor sensitivity 7-fold (P < 0.03) without a reduction in beta1-adrenoceptor density.
Neg (not) Negative_regulation (lowered) of beta1-adrenoceptor
13) Confidence 0.03 Published 1999 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10372729 Disease Relevance 0.73 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox